APA (7th ed.) Citation

KC, M., D, S., AS, L., ET, M., AM, L., L, P., . . . J, D. (2026). Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, 18 October 2023-9 March 2024. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 82(3), e595. https://doi.org/10.1093/cid/ciae405

Chicago Style (17th ed.) Citation

KC, Ma, et al. "Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, 18 October 2023-9 March 2024." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 82, no. 3 (2026): e595. https://doi.org/10.1093/cid/ciae405.

MLA (9th ed.) Citation

KC, Ma, et al. "Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, 18 October 2023-9 March 2024." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 82, no. 3, 2026, p. e595, https://doi.org/10.1093/cid/ciae405.